Lilly's Patent For ADHD Drug Strattera Found Invalid

Law360, New York (August 12, 2010, 7:16 PM EDT) -- A federal judge has sided with generics makers including Teva Pharmaceuticals USA Inc., Mylan Pharmaceuticals and Apotex Inc. and shot down Eli Lilly & Co.'s patent for attention deficit hyperactivity disorder drug Strattera, paving the way for generic versions of the treatment to enter the market.

Judge Dennis Cavanaugh of the U.S. District Court for the District of New Jersey found Thursday that Lilly's 1995 application for the contested method patent had not included test results proving the drugs' utility and thus ran afoul of U.S....
To view the full article, register now.